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Abstract
Histone deacetylase (HDAC) inhibitors represent an emerging class of anticancer agents progressing through clinical
trials. Although their primary target is thought to involve acetylation of core histones, several nonhistone substrates
have been identified, including heat shock protein (HSP) 90, which may contribute towards their antitumor activity.
Glucose-regulated protein 78 (GRP78) is a member of the HSP family of molecular chaperones and plays a central role
in regulating the unfolded protein response (UPR). Emerging data suggest that GRP78 is critical in cellular adaptation
and survival associated with oncogenesis and may serve as a cancer-specific therapeutic target. On the basis of
shared homology with HSP family proteins, we sought to determine whether GRP78 could serve as amolecular target
of the HDAC inhibitor vorinostat. Vorinostat treatment led to GRP78 acetylation, dissociation, and subsequent activa-
tion of its client protein double-stranded RNA-activated protein-like endoplasmic reticulum kinase (PERK). Investiga-
tions in a panel of cancer cell lines identified that UPR activation after vorinostat exposure is specific to certain lines.
Mass spectrometry performed on immunoprecipitated GRP78 identified lysine-585 as a specific vorinostat-
induced acetylation site of GRP78. Downstream activation of the UPR was confirmed, including eukaryotic initiat-
ing factor 2α phosphorylation and increase in ATF4 and C/EBP homologous protein expression. To determine the
biologic relevance of UPR activation after vorinostat, RNA interference of PERK was performed, demonstrating
significantly decreased sensitivity to vorinostat-induced cytotoxicity. Collectively, these findings indicate that
GRP78 is a biologic target of vorinostat, and activation of the UPR through PERK phosphorylation contributes toward
its antitumor activity.
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Introduction
Although cancer has traditionally been considered a disease originating
from genetic alterations resulting in functional loss of tumor-suppressor
genes or gain of oncogenes, epigenetic modifications, or modulating
gene expression through mechanisms other than changes in the under-
lying DNA sequence have emerged as a contributing factor toward
oncogenesis [1]. Regulating gene expression through histone acetylation
represents a formof epigeneticmodification.Histones comprise the pro-
tein backbone of chromatin, and in the acetylated state, the chromatin is
in an open configuration, allowing accessibility for specific transcription
factors and/or the general transcription machinery [2]. The opposing
activities of histone acetyltransferases and histone deacetylases (HDACs)
Abbreviations: ATF, activated transcription factor; CHOP, C/EBP homologous protein;
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result in histone acetylation and deacetylation, respectively, leading to
chromatin remodeling and transcriptional regulation.
Currently, it is widely recognized that HDACs represent promising
therapeutic targets, with an underlying rationale of reversing aberrant
epigenetic states associated with cancer. For example, both aberrant re-
cruitment of HDACs to promoter regions and altered expression of
HDACs have been reported in several tumor types [3,4]. Consequently,
there has been considerable effort in the development of HDAC in-
hibitors as a form of targeted anticancer therapy. A large number of
structurally diverse HDAC inhibitors have been identified demonstrat-
ing preclinical activity in various cancer cell lines [4–6]. Several are cur-
rently in clinical evaluation, including valproic acid and vorinostat
(suberoylanilide hydroxamic acid; Zolinza), which is an HDAC in-
hibitor that has recently been granted Food and Drug Administration
approval for use in cutaneous T-cell lymphoma and is currently being
tested in solid tumors.
Although reversal of aberrant epigenetic changes has been considered
the primary mechanism underlying HDAC inhibitor antitumor ac-
tivity, recent investigations suggest their effects may be considerably
broader, largely based on the expanding number of recently identified
nonhistone substrates of HDACs. At least 50 nonhistone proteins
of known biologic function have been identified, suggesting a more
appropriate term for these enzymes may be protein rather than histone
deacetylases [3,4]. These nonhistone protein targets include transcrip-
tion factors, chaperone proteins, DNA repair proteins, and structural
proteins, and acetylation can either increase or decrease their function
or stability. As these identified HDAC substrates are involved in a di-
verse array of biologic processes, multiple mechanisms may influence
the activity of HDAC inhibitors.
A specific nonhistone target of HDAC inhibitors that has gained re-
cent attention is the chaperone protein heat shock protein 90 (HSP90).
HSP90 is required for the stability and function of numerous client
proteins, including mutated and overexpressed proteins that promote
cancer cell growth and survival, suggesting its potential to serve as a
therapeutic target [7]. Recent investigations demonstrated the potential
of HDAC inhibitors to acetylate HSP90, leading to dissociation of its
client oncoproteins, including ErbB1, ErbB2, bcr-abl, and Akt. Further
investigations identified HDAC6 as the putative target [8,9] and acety-
lation to play a functional role in regulating the HSP90 chaperone cycle
[7]. Although HDAC inhibitors have demonstrated the capacity to in-
fluence HSP90 acetylation, it remains unclear the degree to which this
influences their antitumor activity.
In this report, we identified the endoplasmic reticulum (ER) chap-
erone protein glucose-regulated protein 78 (GRP78) to serve as another
nonhistone target of HDAC inhibitors. GRP78, which shares close
homology with the heat shock family of proteins, serves as the critical
sensor for ER stress and as an activator of the unfolded protein response
(UPR), a highly specific signaling pathway to cope with the accumula-
tion of unfolded or misfolded proteins [10,11]. Recent investigations
suggest that GRP78 may be an important mediator in maintaining
survival in “stressed” cells, such as cancer, and therefore may have thera-
peutic implications [12]. We have shown that GRP78 is acetylated after
HDAC inhibition, leading to dissociation of its client protein double-
stranded RNA-activated protein-like ER kinase (PERK), activation of
the UPR, and abrogating this pathway leads to decreased sensitivity to
vorinostat-induced cytotoxicity. Collectively, these findings indicate
that GRP78 is a biologic target of HDAC inhibitors, and activation
of the UPR through PERK phosphorylation contributes toward its anti-
tumor activity.
Materials and Methods
Cell Lines and Treatment
Cell lines were obtained from theNational Cancer Institute Frederick
Tumor Repository. Cells were maintained in RPMI medium sup-
plemented with either 5% (U251, DU145, or SF539) or 10% (U87
or PC3) fetal bovine serum and glutamate (5 mM). Cell cultures
were maintained at 37°C and 5% CO2. Vorinostat was provided by
Merck Research Laboratories (Whitehouse Station, NJ) through the
NCI-CTEP and was dissolved in DMSO at 1 mM. Valproic acid was
purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in PBS
at 100 mM.
Immunoprecipitation
Cellular extracts were prepared with lysis buffer (50 mM Tris-HCl
[pH 7.4], 150 mM NaCl, 1 mM EDTA, 0.5% Na-deoxycholate,
0.7 μg/ml pepstatin, 1% NP-40, and protease inhibitor cocktail).
Five hundred micrograms of whole-cell lysates was precleared with
a 50-μl mixture of protein A-agarose and protein G-agarose (Roche
Diagnostic Corp., Indianapolis, IN) in a rotator at 4°C overnight.
Fifteen micrograms of rabbit GRP78 polyclonal primary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) was added to the lysate
and incubated for 3 hours at 4°C. Then, 50 μl of protein A-agarose
beads was added to the lysate and incubated overnight at 4°C. Beads
were then pelleted by centrifugation and washed three times with 1)
ice-cold washing buffer, 2) high salt buffer (50 mM Tris-HCl [pH 7.4],
500 mM NaCl, 1 mM EDTA, 0.05% sodium deoxycholate, 0.1%
NP-40, and protease inhibitor cocktail [Roche Diagnostic Corp.]),
and (3) low salt buffer (50 mM Tris-HCl [pH 7.4], 1 mM EDTA,
0.05% sodium deoxycholate, 0.1%NP40, and protease inhibitor cock-
tail [Roche Diagnostic Corp.]). Pellet was then resuspended in sample
buffer, heated at 90°C for 10 minutes, and centrifuged.
Immunoblot Analysis
For the extraction of the whole-cell lysates, cells were harvested by
centrifugation at 1000 rpm for 5 minutes. Cell pellets were washed
once with PBS, gently resuspended in 200 μl of lysis buffer (1% Triton
X-100, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin,
1 μg/ml pepstatin-A, 2 μg/ml aprotinin, 20 mM p-nitrophenyl phos-
phate, 0.5 mM sodium orthovanadate, 1 mM 4-(2-aminoethyl)
benzenesulfonylfluoride hydrochloride) with protease inhibitor cocktail
(Roche Diagnostic Corp.) and phosphatase inhibitor (Sigma-Aldrich),
and incubated on ice with occasional vortexing for 30 minutes. Cell
lysates were centrifuged at 12,000 rpm in a tabletop centrifuge for
15 minutes to remove the nuclear and cellular debris. Proteins were
resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE), transferred to polyvinylidene difluoride (PVDF) mem-
branes (Millipore, Billerica,MA), blocked with 5%milk, and incubated
with primary antibody. Primary antibodies used include anti–acetyl
lysine, anti–total eukaryotic initiating factor 2α (eIF2α) and anti–eIF2α
Ser51 phosphospecific antibody (Cell Signaling Technology, Beverly,
MA), anti–phosphospecific PERK, anti-PERK, anti-ATF4, anti–C/EBP
homologous protein (CHOP), and anti-GRP78 (Santa Cruz Biotech-
nology), and antiactin (Sigma-Aldrich). Secondary antibodies conju-
gated to horseradish peroxidase (Santa Cruz Biotechnology) were
used, and chemiluminescence (Thermo Fisher Scientific, Rockford,
IL) or enhanced chemiluminescence (GE Healthcare, Piscataway, NJ)
was used for detection.
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Liquid Chromatography Coupled with Tandem
Mass Spectrometry
For the detection of discrete acetylation sites of GRP78, liquid chro-
matography coupled with tandem mass spectrometry (LC–MS/MS)
was used. Immunoprecipitated GRP78 was resolved on 4% to 15%
gradient gel (Bio-Rad, Hercules, CA) using SDS-PAGE. Gel bands
corresponding to GRP78 were excised and washed once with water
and twice with 50-mM ammonium bicarbonate in 50% aqueous
methanol. After reduction with triscarboxyethyl phosphine and alkyl-
ation with iodoacetamide, samples are digested overnight with modified
sequencing grade trypsin (Promega, Madison, WI). Peptides were ex-
tracted from the gel slices and concentrated under vacuum centrifuga-
tion. A nanoflow liquid chromatograph (U3000; Dionex, Sunnyvale,
CA) coupled to an electrospray ion trap mass spectrometer (LTQ
Orbitrap; Thermo, San Jose, CA) was used for tandemmass spectrometry
peptide sequencing experiments. Peptides were separated with a C18
reverse phase column (75-μm inner diameter × 15 cm, C18Pepmap;
Dionex) using a 90-minute gradient from 5% to 50% B (A: 2%
acetonitrile/0.1% formic acid; B: 90% acetonitrile/0.1% formic acid).
Five tandem mass spectra were acquired for each MS scan (spray
voltage, 2.5 kV; 30% normalized collision energy; scanning m/z,
450-1600). Sequences were assigned using SEQUEST (Thermo)
and Mascot (www.matrixscience.com) database searches against
SwissProt human protein entries. In addition to acetylysine, oxidized
Figure 2. GRP78acetylation assessed inU251cells treatedwith vorinostat (1μM,24hours) and vehicle control using LC–MS/MS. Thepeptide
was detected at 16.20 minutes in the total ion chromatogram (A) with a mass-to-charge ratio of 855.4332 (B). The tandem mass spectrum
matched thesequence, (K)LGGAcKLSSEDKETOxMEK(A), indicating increased lysine-585acetylation in vorinostat treatedcells; thedetectionof y11
and y12 is consistent with this localization (C). The assignment wasmadewithMASCOTwith an ion score 35.8; SEQUEST XCorr 2.30 ΔCn 0.15.
Figure 1. HDAC inhibitionwith vorinostat leads to GRP78 acetylation
and dissociation with its client protein PERK. The glioblastoma cell
line U251 was exposed to vorinostat (1 μM) for 6 and 24 hours. Cell
lysates were immunoprecipitated (IP) for GRP78 and immunoblot (IB)
wasperformed for (A) acetyl-lysine and (B) PERK. IB for GRP78 served
as loading control.
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methionine, deamidation, and carbamidomethyl cysteine were se-
lected as variable modifications, and as many as three missed cleavages
were allowed. Assignments were manually verified by inspection of
the tandem mass spectra and coalesced into Scaffold reports (www.
proteomesoftware.com). The integrated peak areas for peptide quan-
tification were calculated from extracted ion chromatograms using
QuanBrowser from Xcalibur 2.0. These values were restricted by m/z
(±0.02) and retention time (120 seconds). The masses and isotopic
peak patterns of the target peptides were manually inspected to ensure
proper sequence assignment and to verify peak quality. The signal in-
tensities from unmodified GRP78 peptides were used to normalize the
amount of protein introduced into mass spectrometer.
Protein Synthesis
U251 cells were seeded in six-well plates and allowed to adhere
overnight. Cells were then treated with vorinostat or vehicle control
(DMSO) for the described periods. Before collection, cells were starved
in methionine- and cysteine-free medium for 1 hour and radiolabeled
with 50 μCi/ml [35S]-methionine (specific activity, 1175.0 Ci/mmol)
Easytag Express Protein labeling mix [35S] (PerkinElmer, Waltham,
MA) for 40 minutes. As a positive control, an untreated culture was ex-
posed to cycloheximide (50 μg/ml) at the time of methionine/cysteine–
free medium addition. Medium was aspirated, and cells were lysed by
adding 1% Triton X-100 in 50 mM Tris (pH 7.5), 2 mM EDTA, and
1mMdithiothreitol. Trichloroacetic acid (TCA) precipitation ofmacro-
molecules and scintillation counting were performed as follows: 20 μl
of cell lysate was added to 60 μl of 20% TCA in water (vol./vol.).
The samples were kept on ice for 1 hour and then filtered through
glass filters (GF/C filters; Whatman, Piscataway, NJ) under vacuum.
The filter was washed three times with ice-cold TCA (10%, vol./vol.)
followed by one wash in 95% ethanol and then immersed in 5 ml of
EcoLume Liquid Scintillation Fluid (MP Biomedicals, Solon, OH).
Disintegrations per minute were measured on a Beckman LS6500
scintillation counter (BeckmanCoulter, Brea, CA), and results were nor-
malized as the percent increase or decrease of [35S]-methionine incorpo-
ration compared with that of untreated control cells.
Small Interfering RNA
U251 cells were seeded at 1 × 105 cells per well in six-well plates
and allowed to reach 70% confluence on the day of transfection. The
small interfering RNA (siRNA) constructs (siGENOME SMARTpool
PERK [M-004883-03-0010], siControl nontargeting siRNA pool
[D-001206-13-20], and siGENOME SMARTpool reagents) were
purchased from Dharmacon (Lafayette, CO). Cells were transfected
with 50 nM siRNA in Opti-Mem medium (Invitrogen Life Technol-
ogies, Carlsbad, CA) with 5% FCS according to manufacturer’s pro-
tocol. Forty-eight hours after transfection, cells were trypsinized and
plated for clonogenic survival, and the remaining cells were used for
Western blot.
Clonogenic Survival
Cells were seeded as single cells in six-well plates and allowed to
adhere for 6 hours, treated with vorinostat (1 mM) or vehicle control
(DMSO) for 48 hours, then medium was replaced with drug-free
medium, and cells were allowed to incubate for 10 to 14 days. Plates
were then stained with crystal violet, and colonies consisting of 50 or
more cells were manually counted. Results were normalized to the
colony-forming efficiency of the vehicle control.
Statistical Analysis
The statistical analysis was done using a Student’s t test. A probability
level ofP < 0.05was considered significant.Data are presented asmean ±
SD from three independent experiments.
Results
GRP78 Is a Molecular Target of the HDAC
Inhibitor Vorinostat
Because the ER chaperone protein GRP78 is a member and shares
close homology with the heat shock family of proteins, a previously de-
scribed target of HDAC inhibitors [3,8,13], we sought to determine
whether GRP78 could also be modulated by HDAC inhibition. Initial
studies focused on U251, a glioblastoma cell line that has been previ-
ously described to both aberrantly express and be reliant on GRP78 for
Figure 3. HDAC inhibitors activate the UPR. Western blot was performed on U251 cells in a time course manner to determine whether
HDAC inhibitors from disparate molecular classes can activate PERK (P-PERK), a key signaling pathway associated with the UPR. The HDAC
inhibitors used include (A) the hydroxamic acid vorinostat (1 μM) and (B) the short-chain fatty acid valproic acid (2.5 mM). (C) Glioblastoma
(U251, U87, SF539) and prostate cancer (DU145, PC3) cell lines were treated with vorinostat (1 μM) or vehicle control for 24 hours. Western
blot was performed on cell lysates to evaluate for activated PERK (P-PERK).
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its continued proliferation [12]. U251 cells were exposed to a clinically
relevant concentration of vorinostat (1 μM) [14] or vehicle control in
a time course manner. Cell lysates were then immunoprecipitated for
GRP78 followed by immunoblot analysis with an antibody that recog-
nizes anti–acetylated lysine residues. As shown in Figure 1A, GRP78 is
acetylated after 6 and 24 hours of exposure to vorinostat. We next
sought to determine whether vorinostat-induced GRP78 acetylation
could have a functional consequence of dissociation with its client pro-
teins, the central process involved in UPR activation. Of the known
client proteins associated with GRP78, our initial investigations focused
on the PERK. As demonstrated in Figure 1B, GRP78 dissociates with
its client protein PERK in a time course manner consistent with protein
acetylation after vorinostat exposure. In addition to GRP78 acetylation
and PERK dissociation, both studies demonstrate a modest increase in
GRP78 expression after vorinostat exposure, which represents a recog-
nized downstream signaling consequence of UPR activation [10].
As acetylation of GRP78 has not been previously described, we went
on to define the specific acetylation sites using LC–MS/MS. Immuno-
precipitated GRP78 from U251 cells exposed to vorinostat (1 μM) for
24 hours or vehicle control was separated on SDS-PAGE, and the band
identified by molecular weight as GRP78 was excised. In-gel tryptic
digestion was performed, and the extracted peptides were analyzed by
LC–MS/MS. A nanoflow liquid chromatograph (U3000; Dionex)
coupled to an electrospray ion trap mass spectrometer (LTQ Orbitrap;
Thermo) was used for tandem mass spectrometry peptide sequencing
experiments.Overall, 74%of theGRP78 protein sequence was detected
by LC–MS/MS from tryptic digests. To further evaluate our ability to
localize acetylation sites, 35 (57%) of 61 lysine residues were contained
in peptides sequenced in these experiments. As demonstrated in
Figure 2, we identified lysine-585 of GRP78 to be a specific site of
acetylation after 24 hours of exposure to vorinostat. Using extracted
ion chromatograms for eight peptides, the expression of GRP78 was
observed to increase 2.8 ± 1.0-fold after treatment. These results are con-
sistent with immunoblot experiments (Figure 1), suggesting down-
stream activation of the UPR. Overall, the signal for the acetylated
peptide containing lysine-585 was increased by a factor of 4 after treat-
ment. After normalization for GRP78 expression, which was increased
after vorinostat exposure (consistent with our previous studies), acetyla-
tion on lysine-585 increased an average of 1.5-fold in two biologic re-
plicates after 24 hours of exposure to vorinostat.
HDAC Inhibition Leads to Activation of the UPR
As dissociation of PERK from its chaperone protein GRP78 leads
to PERK dimerization and autophosphorylation, a hallmark of the
UPR, Western blot was performed to determine whether HDAC in-
hibitors have the capacity to activate the UPR signaling cascade. Fig-
ure 3A demonstrates PERK phosphorylation in a time course manner
after exposure to vorinostat (1 μM), with maximal activation between
16 and 24 hours, consistent with the above-described GRP78 acetyla-
tion and PERK dissociation. Similar findings were observed with the
HDAC inhibitor valproic acid using an equitoxic drug concentration
(Figure 3B), suggesting UPR activation after HDAC inhibition is not
agent-specific. To determine whether UPR activation after HDAC in-
hibition is specific to U251, experiments were expanded to a panel of
glioblastoma and prostate cancer cell lines. Although UPR activation
was not present in all cell lines tested, it was shown in the prostate cancer
cell lines DU145 and, to a lesser extent, PC3, confirming this biologic
process was not specific to U251 (Figure 3C). Mechanisms underlying
disparate UPR activation between cell lines remain unclear.
A primary goal of PERK activation involves reducing the workload
on the ER by inhibiting protein biosynthesis, which is accomplished
principally through phosphorylation of the alpha subunit of eIF2α
and selective expression of activated transcription factor 4 (ATF4).
When eIF2α is phosphorylated, the formation of the ternary translation
initiation complex eIF2/GTP/Met-tRNAi
Met is prevented, leading to a
generalized attenuation of translation and protein synthesis. In addition
to a generalized decrease in protein synthesis, phosphorylated eIF2α
selectively promotes translation of ATF4, which subsequently activates
transcription of genes involved in amino acid metabolism and trans-
port, oxidation-reduction reactions, and ER stress–induced apoptosis
[10,15]. As shown in Figure 4A, eIF2α is phosphorylated after HDAC
inhibition in a time course manner consistent with PERK activation.
The functional consequence of eIF2α phosphorylation after HDAC
inhibition was also confirmed, with increased ATF4 expression (Fig-
ure 4A) and decrease in overall protein synthesis determined by
S-methionine incorporation (Figure 4B).
Figure 4. Vorinostat activates downstream signaling of the UPR. (A)
Western blot was performed to evaluate activated eIF2α (P-eIF2α),
translational up-regulation of ATF4, and CHOP expression in U251
cells after vorinostat exposure. (B) Cells were treated with vorinostat
(SAHA) for indicated times or thapsigargin (THG, positive control)
for 24hours andexposed tomethionine/cysteine–freemedium.Cells
were then radiolabeled with [35S]-methionine, and protein lysates
were collected after 40minutes. Counts per minute weremeasured,
adjusted for protein concentration, and normalized to the DMSO
control. Columns, mean; bars, SD. *P < .001 versus control by Stu-
dent’s t test.
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Although the primary effects of UPR activation are designed for
cellular protection, they may also serve to limit damage to other orga-
nelles and can ultimately protect the organism by eliminating cells ex-
periencing prolonged or severe ER stress. Under such conditions, ATF4
induces the transcription factor CHOP, which plays a central role in
mediating cell death pathways associated with the UPR [10]. As dem-
onstrated in Figure 4A, CHOP expression is increased in a time course
manner after vorinostat exposure, suggesting that this pathway contrib-
utes toward vorinostat-induced cytotoxicity. To test this more directly,
we abrogated this pathway using RNA interference to determine the in-
fluence of UPR activation on the antitumor activity of vorinostat. Of
the possible proteins involved in this signaling cascade, we chose to focus
on PERK because it is a key upstream mediator of pathway activation.
Western blot confirmed successful PERK knockdown (Figure 5A).
When compared with both untransfected U251 (control) and those
transfected with scrambled siRNA (si-control), U251 transfected with
siPERK demonstrates a nearly two-fold increase in clonogenic survival
after vorinostat exposure (Figure 5B), supporting the contributory role
of this pathway in vorinostat-induced cytotoxicity.
Discussion
Recent scientific advancements in our understanding of UPR activation
and its primary regulator GRP78 suggest the critical role this adaptive
pathway may play in cancer development and therapeutic resistance
[13]. Our findings demonstrate GRP78 to be a nonhistone target of
the HDAC inhibitor vorinostat. The localization and function of
HDACs within the ER have not been previously described. Therefore,
it would be of considerable interest to identify the specific HDAC(s)
and histone acetyltransferases involved in GRP78 deacetylation/
acetylation to determine their role in UPR activation. In addition, as
our data suggest that this process influences vorinostat activity, such
studies would provide the rationale for the development of isotype-
specific HDAC inhibitors as a strategy for anticancer therapy.
It remains unclear if and how acetylation of GRP78 leads to client
protein dissociation. However, the potential for a direct interaction is
supported by work involving HSP90, in which protein acetylation/
deacetylation was shown to play in integral role in regulating the
chaperone cycle by decreasing client protein affinity [7]. In our studies,
we identified lysine-585 as a specific GRP78 residue acetylated after
vorinostat exposure. Because approximately 57% of the lysine residues
could be sequenced with the described methodologies, it remains un-
known if other acetylation sites exist within GRP78. However, the de-
gree of GRP78 acetylation after vorinostat exposure determined by
mass spectrometry, a 4- and 1.5-fold increase in overall GRP78 acetyla-
tion and when normalized for protein expression, respectively, is in ac-
cord with our Western blot results. Future studies involving mutational
analysis of individual acetylation sites within GRP78 will help to more
definitively define the role of GRP78 acetylation in UPR regulation.
Although a primary function of UPR activation is cytoprotective in
nature, prolonged pathway activation can lead to cell death signaling.
Figure 5. PERK signaling influences vorinostat-induced cytotoxicity. U251 cells were untransfected (control) or transfected with scrambled
siRNA (si-control) and siRNA PERK (si-PERK) for 48 hours. (A) Western blot was performed demonstrating successful PERK knockdown. (B)
The remainder of the cells were seeded in six-well plates, placed in the incubator for 6 hours to allow to attach, treatedwith vorinostat (1 μM)
or vehicle control for 48 hours, replaced with fresh media, and then allowed to grow for 10 to 14 days. Percent survival was normalized
to the colony-forming efficiency of the untreated (vehicle control) cells. Columns, mean; bars, SD. *P < .05 according to Student’s t test
(si-PERK vs control and si-PERK vs si-control).
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The balance between these cytoprotective and cell death fates is not well
understood at present [16,17]. In our studies, vorinostat induced the
expression of CHOP, which is a well-described mediator governing
the lethal effects associated with ER stress response. Further, attenuating
UPR activation through RNA interference of PERK leads to a signifi-
cant decrease in vorinostat-induced cytotoxicity, supporting the role this
pathway plays in its antitumor activity. However, PERK represents only
one of the three central mediators of UPR activation, which also in-
cludes ATF6 and inositol-requiring gene 1. Further study involving
the influence of vorinostat on these pathways may provide additional
insight into the balance of prosurvival and pro–cell death signaling after
UPR activation.
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